MedTrace Logo

A Safety and Tolerability Study of UBX0101 in Patients With Osteoarthritis of the Knee

NCT03513016 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2020-04-20

No results posted yet for this study

Summary

A study to evaluate safety, tolerability, and pharmacokinetics of a single intra-articular injection of UBX0101 in patients diagnosed with painful osteoarthritis of the knee.

Conditions

  • Osteoarthritis, Knee

Interventions

DRUG

UBX0101

Investigational drug intra-articular injection

OTHER

Placebo

Diluent intra-articular injection

Sponsors & Collaborators

  • Unity Biotechnology, Inc.

    lead INDUSTRY

Principal Investigators

  • Jamie Dananberg, MD · UNITY Biotechnology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-16
Primary Completion
2019-03-29
Completion
2019-04-12
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03513016 on ClinicalTrials.gov